This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2002 Aug 15;100(4):1110-1.

doi: 10.1182/blood.V100.4.1110b.

B-CLL: is the enigma of disease heterogeneity about to be revealed?

Neil E Kay¹, Diane F Jelinek

Affiliations

PMID: 12149185
DOI: 10.1182/blood.V100.4.1110b

Free article

Comment

B-CLL: is the enigma of disease heterogeneity about to be revealed?

Neil E Kay et al. Blood. 2002.

Free article

. 2002 Aug 15;100(4):1110-1.

doi: 10.1182/blood.V100.4.1110b.

Authors

Neil E Kay¹, Diane F Jelinek

Affiliation

¹ Mayo Clinic, USA.

PMID: 12149185
DOI: 10.1182/blood.V100.4.1110b

No abstract available

PubMed Disclaimer

Comment on

Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors.
Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE, Corcoran MM, Chapman RM, Thomas PW, Copplestone JA, Orchard JA, Hamblin TJ. Oscier DG, et al. Blood. 2002 Aug 15;100(4):1177-84. Blood. 2002. PMID: 12149195
Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia.
Lin K, Sherrington PD, Dennis M, Matrai Z, Cawley JC, Pettitt AR. Lin K, et al. Blood. 2002 Aug 15;100(4):1404-9. doi: 10.1182/blood-2001-11-0066. Blood. 2002. PMID: 12149224
V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia.
Kröber A, Seiler T, Benner A, Bullinger L, Brückle E, Lichter P, Döhner H, Stilgenbauer S. Kröber A, et al. Blood. 2002 Aug 15;100(4):1410-6. Blood. 2002. PMID: 12149225

Similar articles

Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: potential cure for an incurable disease.
Boyiadzis M, Foon KA, Pavletic S. Boyiadzis M, et al. Expert Opin Biol Ther. 2007 Dec;7(12):1789-97. doi: 10.1517/14712598.7.12.1789. Expert Opin Biol Ther. 2007. PMID: 18034645 Review.
Differences between responsive and intractable chronic lymphocytic leukemia.
Schrek R. Schrek R. Med Hypotheses. 1990 Feb;31(2):81-2. doi: 10.1016/0306-9877(90)90001-u. Med Hypotheses. 1990. PMID: 2325590
Recurrent chromosome abnormalities define nonoverlapping unique subgroups of tumors in patients with chronic lymphocytic leukemia and known karyotypic abnormalities.
Jimenez-Zepeda VH, Chng WJ, Schop RF, Braggio E, Leis JF, Kay N, Fonseca R. Jimenez-Zepeda VH, et al. Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):467-76. doi: 10.1016/j.clml.2013.05.003. Clin Lymphoma Myeloma Leuk. 2013. PMID: 23876845
CLL biology and prognosis.
Dighiero G. Dighiero G. Hematology Am Soc Hematol Educ Program. 2005:278-84. doi: 10.1182/asheducation-2005.1.278. Hematology Am Soc Hematol Educ Program. 2005. PMID: 16304392
Surface profiles for subclassification of chronic lymphocytic leukemia.
Huang PY, Best OG, Belov L, Mulligan SP, Christopherson RI. Huang PY, et al. Leuk Lymphoma. 2012 Jun;53(6):1046-56. doi: 10.3109/10428194.2011.631370. Epub 2012 Apr 3. Leuk Lymphoma. 2012. PMID: 22023531 Review.

See all similar articles

Cited by

A phase I/II trial of oxidized autologous tumor vaccines during the "watch and wait" phase of chronic lymphocytic leukemia.
Spaner DE, Hammond C, Mena J, Foden C, Deabreu A. Spaner DE, et al. Cancer Immunol Immunother. 2005 Jul;54(7):635-46. doi: 10.1007/s00262-004-0626-5. Epub 2004 Dec 17. Cancer Immunol Immunother. 2005. PMID: 15918075 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems
Miscellaneous
- NCI CPTAC Assay Portal